EZH2-Associated Hypermethylated Gene Signature Predicts Immunotherapy Response and Implicates DUSP5 in Tumor-Immune Regulation in Triple-Negative Breast Cancer.

Mingzhan Xue, Sujitha Jeya, Reem Elasad, Sarra Mestiri, Fares Al Ejeh, Mariam Al-Muftah

Abstract read

In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingzhan XueTranslational Oncology Research Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.ORCID 0000-0001-9184-2980

Sujitha JeyaTranslational Oncology Research Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.

Reem ElasadTranslational Oncology Research Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.ORCID 0009-0002-3246-3897

Sarra MestiriTranslational Oncology Research Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.

Fares Al EjehTranslational Oncology Research Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.ORCID 0000-0002-1553-0077

Mariam Al-MuftahTranslational Oncology Research Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.ORCID 0000-0002-3098-9433

Funding

Qatar Biomedical Research Institute IGP8_2026_005

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkerDNA methylationDUSP5EZH2immune regulationimmunotherapyMAPK signalingTriple-Negative Breast Cancer

Identifiers

PMID42192966

DOI10.3390/cancers18101606

PMCPMC13204126

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.